ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

Protocol: 
AAAC7030
Phase: 
III

ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

The overall goal of this study is to compare the effects, good and/or bad, of the chemotherapy drugs carboplatin and isotretinoin on subjects with high risk medulloblastoma and to find out if one or both are better than standard therapy alone. In this study the patient will get either standard therapy alone, standard therapy plus one of the chemotherapy drugs added to the regimen, or standard therapy plus both of the chemotherapy drugs. Both radiation therapy and the drug carboplatin have an anticancer effect when given alone. However, studies have shown that when carboplatin is given along with radiation therapy a greater effect is produced than when either is given alone. In this study we will look at whether giving radiation therapy and carboplatin together can improve the rate of survival of subjects with high risk medulloblastoma. This study will look at whether adding isotretinoin to the standard chemotherapy drugs can improve the rate of survival of children with high risk medulloblastoma.

Are you Eligible? (Inclusion Criteria)

-Subjects must be at least 3 years and up to 21 years of age at the time of
study entry.
-Patients must be newly diagnosed with previously untreated, other than
average risk, medulloblastoma.
-Patients must have had a pre-operative magnetic resonance imaging (MRI) scan
of the brain with and without contrast.
-Patients must also meet all eligibility criteria as outlined in the study
protocol.

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States